Does nonlinear blood-brain barrier transport matter for (lower) morphine dosing strategies?

Gülave, B.; Budda, D.; Saleh, M.A.A.E.W.; Hasselt, J.G.C. van; Lange, E.C.M. de (2023)

Article / Letter to editor

Morphine blood-brain barrier (BBB) transport is governed by passive diffusion, active efflux and saturable active influx. This may result in nonlinear plasma concentration-dependent brain extracellular fluid (brain_ECF) pharmacokinetics of morphine. In this study, we aim to evaluate the impact of nonlinear BBB transport on brain_ECF pharmacokinetics of morphine and its metabolites for different dosing strategies using a physiologically based pharmacokinetic simulation study. We extended the human physiologically based pharmacokinetic LeiCNS-PK3.0, model with equations for nonlinear BBB transport of morphine. Simulations for brain_ECF pharmacokinetics were performed for various dosing strategies: intravenous (IV), oral immediate (IR) and extended release (ER) with dose range of 0.25-150 mg and dosing frequencies of 1-6 times daily. The impact of nonlinear BBB transport on morphine CNS pharmacokinetics was evaluated by quantifying (i) the relative brain_ECF to plasma exposure (AUC_u,brainECF/AUC_u,_plasma) and (ii) the impact on the peak-to-trough ratio (PTR) of concentration-time profiles in brain_ECF and plasma. We found that the relative morphine exposure and PTRs are dose dependent for the evaluated dose range. The highest relative morphine exposure value of 1.4 was found for once daily 0.25 mg ER and lowest of 0.1 for 6-daily 150 mg IV dosing. At lower doses the PTRs were smaller and increased with increasing dose and stabilized at higher doses independent of dosing frequency. Relative peak concentrations of morphine in relation to its metabolites changed with increasing dose. We conclude that nonlinearity of morphine BBB transport affects the relative brain_ECF exposure and the fluctuation of morphine and its metabolites mainly at lower dosing regimens.

• All authors: Gülave, B.; Budda, D.; Saleh, M.A.A.E.W.; Hasselt, J.G.C. van; Lange, E.C.M. de
• Date: 2023-08-01
• Journal: European Journal of Pharmaceutical Sciences
• Volume: 187
• DOI: doi:10.1016/j.ejps.2023.106482